Media

Racura Oncology chief executive officer Dr Daniel Tillett talked with Proactive about the company’s key milestones this quarter, including the treatment of the first patient with its lead asset, RC220, a reformulated version of bisantrene. Watch the full interview here.

In this exclusive interview with The Capital Compass, Dr. Pete Smith from Racura Oncology discusses the company’s groundbreaking work on RC220, a reformulated cancer drug with a proven history of efficacy and safety. Watch the full interview here.

Racura Oncology Ltd (ASX:RAC, OTC:RAONF) has successfully dosed the first patient with the combination of its lead drug RC220 and doxorubicin in its Phase 1 clinical trial targeting advanced solid tumours.  Read the full article here.

The Australian reports Racura Oncology has achieved a major milestone, as the company has safely and successfully dosed its first patients for its Phase 1 clinical trial in advanced solid tumours. Read the full report here.

Racura CEO and Managing Director Dr Daniel Tillett speaks with ausbiz about the company’s recent major milestone – the first patient has been safely and successfully dosed for the RC220 Phase 1 clinical trial in advanced solid tumours. Watch the full interview via this link.

Racura Oncology CEO and MD Daniel Tillett speaks with Proactive about the activation of the first Australian clinical site for the RC220 Phase I solid tumour trial. Dr Tillett confirms that the trial is now underway and open to patient enrolment. Watch the full interview below. Additional report can be found here.

Racura Oncology Executive Chair Dr Peter Smith speaks with Stockhead about the recent ethics approval for the company’s RC220 bisantrene Phase 1 clinical trial in solid tumour. The full report can be accessed via this link.

Racura Oncology Executive Chair Dr Peter Smith speak with Proactive about the approval the company has received from the Bellberry Human Research Ethics Committee (HREC). The approval allows the company to move forward with its Phase 1 clinical trial for RC220, a new formulation of bisantrene. The full report can be accessed via this link.

Racura CEO and Managing Director Dr Daniel Tillett speaks with ausbiz’s Juliette Saly about the ethics approval for the RC220 bisantrene Phase 1 clinical trial. Watch the full video via this link.